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families of the children to better defend their interest before the health authorities
in terms of expenditure (medical or other) for which the part remaining their re-
sponsibility is increasing significantly.
Systemic Disorders/Conditions – Clinical Outcomes Studies
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OBJECTIVES: Iron chelators (deferasirox or desferrioxamine) are essential to pa-
tients who need life-long blood transfusion (e.g. -Thalassemia). However, in 2010,
the US Food and Drug Administration (FDA) had issued a warning on potential
adverse events associatedwith iron chelators, especially deferasirox. The objective
of this retrospective cohort study was to compare the risk of renal impairment,
hepatic impairment, and gastrointestinal bleeding in patients with transfusion-
dependent anemia using deferasirox or desferrioxamine.METHODS: Patients with
transfusion-dependent anemia (sickle cell disease, -thalassaemia,myelodysplas-
tic syndrome and aplastic anemia) and were prescribed iron chelators (deferasirox
or desferrioxamine) were identified from the 20052009 Taiwan’s National Health
Insurance database. Cox proportional hazards models were used to assess the
association between iron chelators and occurrences of adverse events (renal im-
pairment, hepatic impairment, and gastrointestinal bleeding). All models adjusted
for age, sex, drug exposure (days), type of transfusion-dependent anemia andmed-
ical history. RESULTS: Patients were categorized into deferasirox (n180), desfer-
rioxamine (n586),and mixed users (n202), based on the drug they received dur-
ing the follow-up. The crude rates of adverse events were 4.14, 3.16 and 0.65 per
10,000 person-year in deferasirox, desferrioxamine and mix users, respectively.
After adjusting covariates, there was no association between deferasirox and ad-
verse events (hazard ratio [HR]0.84; 95% CI, 0.59–2.00) compared to desferrioxam-
ine users. CONCLUSIONS: In this population-based analysis, transfusion-depen-
dant anemia patients using deferasirox and desferrioxaminewere at similar risk of
adverse events.
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OBJECTIVES: To assess the hematological effects Angiotensin-converting enzyme
(ACE-I) inhibitors and Angiotensin II receptor blockers (ARB) in patients without
concomitant renal impairment. METHODS: In the present retrospective cohort
study we used the Maccabi Healthcare Services’ database to identify new users of
ACE-I (N14754) ARB (N751), or calcium channel blockers (CCB, N3087) with
available hemoglobin (Hb) tests between 2004 and 2009. Excluded were patients
purchasing drugs from more than one medication class, diagnosed with renal im-
pairment or cancer. Median Hb levels one year before and after first medication
purchase (index date)were calculated and compared according to the proportion of
days coveredwithmedication class. RESULTS: Persistent use of ACE-I and ARBwas
associated with a significant decrement in hemoglobin level. Patients at the high-
est PDC level were at a significantly higher risk of developing anemia among ACEI
(OR  1.59, p0.001), and ARB (OR  2.21, p0.05). The relationship between CCB
therapy andHb decrementwas substantially weaker. CONCLUSIONS:Hb levels are
reduced during the first year of ACE-I or ARB therapy. This association is dose-
dependent and is not likely to be caused by artifacts related to patient adherence.
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OBJECTIVES: Severe non-malignant pain affects a large number of patients. Opi-
oids are an important option for analgesia. However, there is relatively little infor-
mation about the comparative safety of opioids. We sought to compare the safety
and tolerability of commonly used opioids in non-malignant pain through network
meta-analyses of randomized controlled trials (RCTs). METHODS: Medline and
Embase were searched from 2000 to 2011 for RCTs comparing commonly used
opioids (tramadol, oxycodone, hydrocodone, propoxyphene, codeine) in non-ma-
lignant pain. Studies were assessed for inclusion/exclusion based on a prespecified
protocol. Two reviewers undertook data extraction independently. Any disagree-
ment was resolved by a third reviewer. A networkmeta-analysis was used to com-
bine direct and indirect evidence for safety outcomes reported in the trials. Based
on the incidence of adverse events (AEs) for each intervention, a probability-based
ranking (probability (P) of beingworst) was generated usingWinBUGS.RESULTS:Of
the 1156 studies, 5 RCTs enrolling 1399 patients were eligible for inclusion. The
most commonly reported AEs were nausea, vomiting, somnolence, dizziness,
headache, constipation and dry mouth. Withdrawals due to AEs were most com-
monly observedwith codeine (P42%) followed by hydrocodone (P28%), tramadol
(P19%), and oxycodone (P10%). The probability of occurrence of nausea and
somnolence was the highest with codeine. Dizziness was most frequently associ-
ated with oxycodone (P 53%). However, the incidence of dizziness and headache
was the lowest with codeine. Tramadol was observed to be associated with the
highest (P40%) incidence of vomiting, while hydrocodone had the lowest inci-
dence (P15%). CONCLUSIONS: Codeinewas observed to have the highest incidence
of withdrawals due to AEs. It was observed that the probability of occurrence of any
particular AE varied across included opioid analgesics. Codeine was observed to have
been more frequently associated with nausea/somnolence while tramadol and oxy-
codone had the highest incidence of vomiting and dizziness respectively.
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OBJECTIVES: Although hyponatremia (HN) is the most common electrolyte abnor-
mality in hospitalized patients, little is known regarding the influence of HN and its
management on patient outcomes and healthcare resource usage. TheHNRegistry
is a novel prospective effort to document the clinical and healthcare outcomes of
HN and its management. Results for the first 25 HN patients enrolled are described
here.METHODS:After informed consent or waiver, data were extracted frommed-
ical charts of enrolled patients. HN was defined as a serum sodium  130 mmol/L.
The pilot data were summarized appropriately by sample size and for categorical
data by percentage. Subjects who had HN on admission were categorized as pre-
existing HN patients and those who were admitted for another reason and devel-
oped HN while in the hospital were categorized as hospital-acquired HN patients.
RESULTS: Overall, only 20% of the enrolled patients received any pharmacologic
management for HN and approximately 44% were discharged with persistent HN
(21% of treated vs. 79% of untreated). Among the patients discharged with HN, 55%
had a previous episode of HN. In addition, among the patients with previous HN,
46% were discharged with persistent HN. The length of stay for patients with pre-
existing HN was 1.3 days longer compared to patients with hospital-acquired HN.
These findings will be further evaluated and reported as more data in this large
registry study are accumulated. CONCLUSIONS:Amonghospitalized patients, HN is
frequently untreated, and nearly half of patients are discharged without normaliza-
tion of serum sodium. HN commonly persists through several hospital admissions.
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OBJECTIVES: The United States is experiencing an obesity epidemic with 67% of
adults being either overweight or obese. While it is known that excessive weight
increases the opportunity for skin infections, this relationship has not been well
studied. This study contributes to the knowledge about the relationship between
these two conditions.METHODS: Using the H-CUP national database for inpatient
hospitalizations, this study analyzed the data fromhospitals in the Southern states
for the number of skin and soft tissue infections in 2003, 2005 and 2007 in adults.
The proportion of patients who were also coded as obese in this population was
quantified. Two t-tests were performed comparing the average length of stay for
patients who were obese and not obese and the average total hospital charges for
patients who were obese and not obese. Two linear regressions analyzed the im-
pact of obesity on the cost of health care by using length of stay and total hospital
charges as dependent variables. RESULTS: The proportion of patients hospitalized
for skin and soft tissue infections who were also obese increased from 48.09% in
2003 to 51.7% in 2007. The average length of stay was 7.97 days for non-obese
patients verses 4.6 days for patients coded as obese which was statistically signif-
icant. The average total hospital charges were $26,653 for non-obese patients com-
pared to $20,876 for obese patients. This was also statistically significant. Surpris-
ingly, the co-morbidity of obesity has a negative predictive value for both hospital
length of stay and total hospital charges.CONCLUSIONS: It is possible that patients
who are obese are being discharged sooner because of differences in severity of
infections. More research is needed to determinewhether obesity is a causal factor
in skin and soft tissue infections and how this is affecting the cost and delivery of
health care.
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OBJECTIVES: We examined proportions of patients: a) monitored for TIO after
receiving 10, 20, and 30 units of red blood cells (RBC) and b) receiving iron
chelation therapy (ICT). We also examined overall survival (OS) among: a) moni-
tored vs. unmonitored; b) ICT-treated vs. ICT-untreated groups.METHODS: Medi-
cal records of patients 18 years receiving 10 RBC units 6 months before data
abstraction were identified at the Moffitt Cancer Center and Research Institute
(December 2009-June 2010). Observation period spanned from 10th RBC unit to end
of follow-up (i.e., death, clinic departure, or end of observation period). TIO moni-
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